Biblio

Found 16 results
Author Keyword Title Type [ Year(Asc)]
Filters: First Letter Of Title is D  [Clear All Filters]
2011
F. Joly, Ray-Coquard, I., Fabbro, M., Donoghoe, M., Boman, K., Sugimoto, A., Vaughan, M., Reinthaller, A., Vergote, I. B., Ferrandina, G., Dell'Anna, T., Huober, J., and Pujade-Lauraine, E., Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial., Gynecol Oncol, vol. 122, no. 2, p. 232, 2011.
G. J. S. Rustin, Vergote, I. B., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G. B., Jakobsen, A., Sagae, S., Greven, K., Parmar, M. K. B., Friedlander, M. Leonard, Cervantes, A., Vermorken, J. B., and Intergroup, G. Cancer, Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, vol. 21, pp. 419-23, 2011.
L. C, Simes, R. J., Gebski, V., Wollschlaeger, K., Plante, M., Vergote, I. B., Maenpaa, J. U., Ferrero, A., Pisano, C., Parma, G., Berton-Rigaud, D., der W, S., Bentley, J., Reinthaller, A., Schmalfeldt, B., Hirte, H., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. , Int J Gynecol Cancer , vol. 21, no. 12 Suppl 3, 2011.
S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial., Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
2003
F. H. van Wijk, Aapro, M. S., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A. M., de Oliveira, C. F., Tumolo, S., V. di Palumbo, S., Piccart, M. J., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M. A., Presti, M., Scarabelli, C., Splinter, T. A., Ploch, E., Beex, L. V., Huinink, W. W. ten Bok, Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E., Teodorovic, I., Coens, C., Vergote, I. B., Vermorken, J. B., Research, E. Organisati, and Group, Tof Cancer, Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group, Ann Oncol, vol. 14, pp. 441-8, 2003.
F. H. van Wijk, Aapro, M. S., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A. M., de Oliveira, C. F., Tumolo, S., V. di Palumbo, S., Piccart, M. J., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M. A., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V., Huinink, W. W. ten Bok, Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I. B., and Vermorken, J. B., Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group., Ann Oncol, vol. 14, no. 3, pp. 441-8, 2003.